Open AccessDot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma
Author(s) -
Yang Qu,
Li Liu,
Jiajun Wang,
Wei Xi,
Xinbing Yu,
Qi Bai,
Ying Xiong,
Qilai Long,
Jiejie Xu,
Jianming Guo
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.12476
Subject(s) - medicine , renal cell carcinoma , clear cell renal cell carcinoma , cell , oncology , cancer research , biology , genetics
Disruptor of telomeric silencing 1-like (Dot1l), a histone methyltransferase that targets the histone H3 lysine 79 (H3K79), has been reported that its high expression is associated with various cancers, while the association between Dot1l expression and clear-cell renal cell carcinoma (ccRCC) is still unknown.